Stilla Technologies announces Daniel Wang to its Board along with raising €20m Series B funding led by TUS-Holdings

– FRANCE, Paris –  Stilla Technologies today announced that it has just raised €20 million in a Series B funding round that brought in a new investor, the Chinese group TUS-Holdings, alongside the participation of existing investors Illumina Ventures, Kurma Partners, LBO France, Paris Saclay Seed Funds, BNP Paribas Développement and Idinvest Partners.

Daniel Wang, CEO of Tuspark Europe, the European subsidiary of TUS‐Holdings will join the Board of Directors.

Rémi Dangla, Cofounder and CEO of Stilla Technologies said: “We will use the funds to boost the development of our next-generation solution, which will feature superior analytical performance including 6-color detection capabilities. Our future focus will be to apply our state-of-the-art technology to clinical diagnostics, to the benefit of patients.”

he adds: “By bringing TUS‐Holdings on board, we also look to rapidly expand our activities in China and throughout Asia, while maintaining strong growth of the business in Europe and the United States. Following our Series A round in October 2018, the company has been expanding very rapidly, experiencing strong sales growth and making exciting progress with its pipeline of new products. The new Series B round will allow us to continue on this successful course at an even faster pace.”

“I am thrilled to welcome TUS‐Holdings as one of Stilla’s investors and to appoint the Head of TUS’ European subsidiary, Daniel Wang, as a new member of our board. China has always been a key market for Stilla. Over the years, we have built a successful partnership with our local distributor and partner Apexbio/Cycloud. I see a very strong future for our Crystal Digital PCR technology in China, and it is great to have Daniel helping us to build the best strategy to seize opportunities there,” added Mr. Dangla.

“TUS is convinced of Stilla’s promising potential, both in terms of technology and market perspective. We believe that the company has a bright future in China. As such, we’re thrilled to add Stilla to our portfolio of more than 30 life science and biotech companies. TUS will spare no effort to facilitate Stilla’s growth, including by granting the company access to our innovation ecosystem and network,” said Daniel Wang, CEO of Tuspark Europe, the European subsidiary of TUS‐Holdings.

Since 2016, Stilla Technologies has been providing research organizations specialized in molecular biology and genetic analysis with its Naica System, a ground‐breaking digital PCR solution that enables scientists to detect and quantify DNA mutations with unrivalled precision. The $2‐billion digital PCR market targeted by Stilla Technologies is poised to become the new standard in molecular biology. Stilla Technologies launched the first generation of the Naica System in 2016 and generated first revenues in 2017.

About Stilla’s Naica System

The Naica System is a highly sensitive digital PCR solution that runs on the company’s next‐generation genetic testing and nucleic acid quantification technology, Crystal Digital PCR. The Naica System is uniquely capable of characterizing multiple types of nucleic acids with its three‐color detection capability. Its ease of use and fastest time to results — in two hours and 30 minutes —set this innovative technology apart on the digital PCR market. The Naica System supports a wide range of genetic tests and molecular biology assays — including liquid biopsy tests for cancer diagnostics, viral load quantification, prenatal testing, and GMO detection. Overall, the Naica System’s superior performances make it a preferred technology for precision medicine research and therapeutic monitoring.

About Stilla Technologies

Founded in 2013 at Ecole Polytechnique, Stilla Technologies is a Paris‐based European life sciences company that focuses on accelerating the development of next‐generation genetic tests by providing a ground‐breaking and flexible digital PCR solution: the Naica System. Taking advantage of cutting‐edge microfluidic innovations, Stilla aims to make dPCR a lab commodity for all areas of the life sciences. Stilla actively advises and supports its customers worldwide through its dynamic and multidisciplinary R&D team, with expertise spanning from microfluidics to chemistry, including molecular biology and AI.

For more information:

About TUS‐Holdings

TUS‐Holdings was originated from the former Tsinghua University Science Park, the largest University Park in the world. It has invested over 200 parks/incubators globally, having a full supply‐chain incubation with the unique model of “incubation + investment + M&As”. The group has demonstrated return‐focused fund management capabilities with currently more than 35 venture and industry funds, and this investment to Stilla is through its Luxembourg CLIIF fund. TUS is actively expanding its healthcare sector through investments focusing on IVD and Precision medicine, medical instruments and healthcare services. The total investment in this sector has reached over EUR 300 million.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.